Skip to content

Transperineal Laser Ablation for treatment of LUTS due to benign prostatic obstruction

Transperineal Laser Ablation for treatment of LUTS due to benign prostatic obstruction - TPLA for BPO

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON55617
Enrollment
20
Registered
2018-08-31
Start date
2018-10-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic obstruction enlarged prostate

Interventions

All subjects undergo a transperineal laser ablation of their prostate under local anaesthesia using the Echolaser® system. Two to four laser fibres are placed in the prostate and laser light induces

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Male - 40 years of age - Peak urinary flow rate (Qmax): *5 mL/sec to *15 mL/sec, with a minimum voided volume of *125 mL, measured with uroflowmetry or urodynamic investigation - Post-void residual (PVR): * 250 mL - Prostate volume: * 30 and * 80 cc - Urodynamic investigation proven bladder outlet obstruction

Exclusion criteria

Exclusion criteria: - Previous invasive prostate intervention (TURP, laser, ablation, etc.) - History of prostate or bladder cancer - Indwelling Foley catheter or clean intermittent catheterization (CIC) - A clinical suspicion for prostate cancer (without recent (

Design outcomes

Primary

MeasureTime frame
The main study parameter for feasibility is the number of successful TPLA procedures. For safety the main study parameter is the number of grade 3 adverse events based on the CTCAE v5.0 within the first 30 days.

Secondary

MeasureTime frame
The secundairy study parameters are functional outcomes for voiding using uroflow and IPSS and erectile function using the IIEF. Furthermore tissue changes are evaluated with imaging.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 3, 2026